Skip to content

VOLITIONRX LTD

VNRX

CIK 0000093314 · In Vitro & In Vivo Diagnostic Substances · NYSE

  • VOLITIONRX LTD (until 2026-06-18)
  • STANDARD CAPITAL CORP (until 2011-09-29)
← back to feed
Revenue (TTM)
$2.27M
+40.0% YoY Q1 May 2026
Net Income (TTM)
−$23.75M
+13.4% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.20
+38.0% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-983.0%
Q1 May 2026
Net Margin
-1,048.4%
Q1 May 2026
Free Cash Flow (TTM)
−$26.91M
Q1 May 2026
Cash
$1.12M
Q1 May 2026
Total Debt
$6.92M
Q1 May 2026
Shares Outstanding
8.33M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings